APF# NDA

Related by string. * : APF# Phase . APF# / NDAS . nda . Nda . NDAs : NDA convenor Sharad Yadav . NDA convener George . NDA convener . NDA submission . NDA Convener George . NDA convenor George . Alliance NDA . erstwhile NDA . Intermezzo ® NDA . NDA Convenor George . Alliance NDA convenor . lorcaserin NDA . NDA convenor . Investigational NDAs . NDA Convenor . NDA resubmission . Drug Applications NDAs * *

Related by context. Frequent words. (Click for all words.) 65 BLA submission 65 Complete Response Letter 65 Biologics License Application BLA 62 Marketing Authorization Application MAA 62 Marketing Authorization Application 61 Complete Response letter 61 IND submission 61 Biologics License Application 60 Complete Response 59 sBLA 59 supplemental Biologics License Application 59 Approvable Letter 58 NDA submission 58 Act PDUFA date 58 PDUFA date 58 BioDelivery Sciences 57 resubmission 57 APF# 56 sNDA 56 Pirfenidone 56 Palatin Technologies Inc. 56 New Drug Application 56 Paragraph IV 56 Rhucin 55 OFIRMEV 54 IND enabling 54 Omnitrope 54 alogliptin 54 Acetavance 54 Nasdaq VRTX 54 SFDA approval 53 Onsolis 53 Antegren 53 PREOS 53 Krystexxa 53 Replagal 53 Investigational Device Exemption 53 registrational trial 53 orphan designation 53 ponatinib 53 JZP 6 53 registrational 53 Exalgo 53 Strativa 53 Company NASDAQ MDCO 53 Arpida 52 StaphVAX 52 Lumizyme 52 Flutiform 52 INDs 52 Horizant 52 QRxPharma 52 alvimopan 52 Pivotal Phase III 52 Drug Application 52 Phase IIa trial 52 IMPAX Laboratories Inc. 52 Rhucin ® 52 L DOS# 52 FavId 52 phase IIb 52 Citizen Petition 52 Vilazodone 52 cervical cancer vaccine Cervarix 52 Intellipharmaceutics 52 Phase III Clinical Trial 52 CHMP opinion 51 By Hayley Tsukayama 51 Act PDUFA 51 maribavir 51 BENLYSTA 51 L MTP PE 51 pralatrexate 51 approvable letter 51 Ligand Pharmaceuticals Incorporated 51 Zelrix 51 Investigational 51 Indiplon 51 confirmatory Phase 3 51 Fast Track designation 51 FIRAZYR 51 MONOVISC 51 ONSOLIS 51 Tranzyme Pharma 51 Icatibant 51 NASDAQ ARIA 51 vilazodone 50 biogeneric 50 Phase IIa clinical trials 50 Restanza 50 EPIX Pharmaceuticals 50 Jerini 50 Genentech Roche 50 Promacta 50 NYSE MYL 50 ATryn R 50 Renvela 50 Pivotal Trial 50 Afrezza 50 FDA 50 Orphan Drug Status

Back to home page